Oncology Research Today is a free monthly online journal that collates and summarizes the latest research about Oncology, including details on cancer, surgery, chemotherapy, radiotherapy.

A combined pain consultation and pain education program decreases average and current pain and decreases interference in daily life by pain in oncology outpatients: A randomized controlled trial.

Oldenmenger WH, Sillevis Smitt PA, van Montfort CA, de Raaf PJ, van der Rijt CC

Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands.

Pain education programs (PEP) and pain consultations (PC) have been studied to overcome patient-related and professional-related barriers in cancer pain management. These interventions were studied separately, not in combination, and half of the studies reported a significant improvement in pain. Moreover, most PEP studies did not mention the adequacy of pain treatment. We studied the effect of PC combined with PEP on pain and interference by pain with daily functioning in comparison to standard care (SC). Patients were randomly assigned to SC (n=37) or PC-PEP (n=35). PEP consisted of patient-tailored pain education and weekly monitoring of pain and side effects. We measured overall reduction in pain intensity and daily interference over an 8-week period as well as adequacy of pain treatment and adherence. The overall reduction in pain intensity and daily interference was significantly greater after randomization to PC-PEP than to SC (average pain 31% vs 20%, P=.03; current pain 30% vs 16%, P=.016; interference 20% vs 2.5%, P=.01). Adequacy of pain management did not differ between the groups. Patients were more adherent to analgesics after randomization to PC-PEP than to SC (P=.03). In conclusion, PC-PEP improves pain, daily interference, and patient adherence in oncology outpatients.

Published 21 October 2011 in Pain, 152(11): 2632-9.
Full-text of this article is available online (may require subscription).

Articles on Oncology published 21 October 2011:

Patterns of missing mini mental status exam (MMSE) in radiation therapy oncology group (RTOG) brain cancer trials.   J Neurooncol, 105(2): 383-95.

The Mini Mental Status Exam (MMSE) instrument has been commonly used in the Radiation Therapy Oncology Group (RTOG) to assess mental status in brain cancer patients. Evaluating patient factors in relation to patterns of incomplete MMSE assessments can provide insight into predictors of missingness and optimal MMSE collection schedules in brain cancer clinical trials. This study examined eight RTOG brain cancer trials with ten treatment arms and 1,957 eligible patients. Patient data compliance ... [Abstract] [Full-text]

Articles on Oncology published 20 October 2011:

Moving CLABSI Prevention beyond the Intensive Care Unit: Risk Factors in Pediatric Oncology Patients.   Infect Control Hosp Epidemiol, 32(11): 1079-85.

Background and Objective. Central line-associated bloodstream infections (CLABSIs) frequently complicate the use of central venous catheters (CVCs) among pediatric patients with cancer. Our objectives were to describe the microbiology and identify risk factors for hospital-onset CLABSI in this patient population. Design. Retrospective case-control study. Setting. Oncology and stem cell transplant units of a freestanding, 396-bed quaternary care pediatric hospital. Participants. Case ... [Abstract] [Full-text]

Ten problematical issues identified by pathology review for multidisciplinary gynaecological oncology meetings.   J Clin Pathol.

Pathology review of gynaecological cancer specimens is often carried out as part of the working of gynaecological oncology multidisciplinary team meetings. This review describes the author's experience regarding the most common issues identified during this process. Ten subjects are covered; these range from histopathological interpretational errors to non-interpretational areas, for example, inappropriate use of the term 'microinvasive cervical carcinoma' and the use of inappropriate staging ... [Abstract] [Full-text]

Current trends and emerging future of indocyanine green usage in surgery and oncology: A literature review.   Cancer, 117(21): 4812-22.

Ever since Kitai first performed fluorescent navigation of sentinel lymph nodes (SLNs) using indocyanine green (ICG) dye with a charge-couple device and light emitting diodes, the intraoperative use of near infrared fluorescence has served a critical role in increasing our understanding in various fields of surgical oncology. Here the authors review the emerging role of the ICG fluorophore in the development of our comprehension of the lymphatic system and its use in SLN mapping and biopsy in ... [Abstract] [Full-text]

Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: A report from the Children's Oncology Group.   Cancer, 117(21): 4966-76.

[Abstract] [Full-text]

Articles on Oncology published 19 October 2011:

Discordance in Perceived Needs Between Patients and Physicians in Oncology Practice: A Nationwide Survey in Korea.   J Clin Oncol.

PURPOSEIdentification of supportive care needs in patients with cancer is essential for planning appropriate interventions. We aimed to determine patient-physician concordance in perceived supportive care needs in cancer care and to explore the predictors and potential consequences of patient-physician concordance. PATIENTS AND METHODSA national, multicenter, cross-sectional survey of patient-physician dyads was performed, and 97 oncologists (participation rate, 86.5%) and 495 patients ... [Abstract] [Full-text]

Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study.   J Clin Oncol.

PURPOSETo assess the feasibility of adding dose-intensive topotecan and cyclophosphamide to induction therapy for newly diagnosed high-risk neuroblastoma (HRNB). PATIENTS AND METHODSEnrolled patients received two cycles of topotecan (approximately 1.2 mg/m(2)/d) and cyclophosphamide (400 mg/m(2)/d) for 5 days followed by four cycles of multiagent chemotherapy (Memorial Sloan-Kettering Cancer Center [MSKCC] regimen). Pharmacokinetically guided topotecan dosing (target systemic exposure with area ... [Abstract] [Full-text]

Company stock prices before and after public announcements related to oncology drugs.   J Natl Cancer Inst, 103(20): 1507-12.

Background Phase III clinical trials and Food and Drug Administration (FDA) regulatory decisions are critical for success of new drugs and can influence a company's market valuation. Knowledge of trial results before they are made public (ie, "inside information") can affect the price of a drug company's stock. We examined the stock prices of companies before and after public announcements regarding experimental anticancer drugs owned by the companies. Methods We identified drugs ... [Abstract] [Full-text]

© 2005-2011 Oncology Research Today. All Rights Reserved.